全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用：99美元
投递稿件

查看量下载量

相关文章

更多...

Evaluation of Adherence to Nevirapine for Prevention of Mother-to-Child Transmission amongst Infants of HIV Positive Mothers in the First 6 Weeks of Life in Lagos Nigeria

DOI: 10.4236/wja.2019.92006, PP. 70-84

Keywords: Adherence, Infants, Antiretroviral Prophylaxis, Maternal/Caregiver Verbal Reports, Nevirapine, Six Weeks

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background: Over 90% of infection in children is acquired through mother to child transmission (MTCT). Nevirapine’s efficacy, safety and affordable cost make it the most preferred non-nucleoside reverse transcriptase inhibitor (NNRTI) for paediatric prophylactic use in resource limited settings. There are very few studies on pediatric adherence to antiretroviral prophylaxis, especially in very young infants. The objective of the study was to evaluate the adherence to nevirapine for prevention of mother to child transmission (PMTCT) amongst infants of HIV positive mothers in the first 6 weeks of life. Methods: This was a questionnaire based prospective cross-sectional multicenter study initiated in July 2015 and concluded in December 2017. The study was carried out at the Aids Prevention in Nigeria (APIN/HIV) human immunodeficiency paediatric clinics of the Lagos University Teaching Hospital (LUTH), Idi-Araba, Lagos State, 68 Nigerian Army Reference Hospital Yaba (68NARHY) Lagos, Nigeria and the Holy Family Catholic Hospital, Festac Town, Amuwo Odofin, Lagos State. Nevirapine adherence, in infants of 0 - 6 weeks was measured by maternal verbal reports. Results: Eighty-one (81) infants receiving nevirapine within the age of 0 - 6 weeks completed the study. Majority of the infants started treatment at birth (32%) and after 4 weeks (31%). 54% of the 81 respondents do not miss or skip their doses while 46% of respondents skip doses. Majority of the respondents 18 (49%) missed their doses for 24 - 48 hours while 25% missed their doses because they were away from home and 23% ran out of pills. 85.2% took ≥95% of the prescribed medications (good or high adherence ), 8.2% took 80% - 95% of doses (moderate adherence) while 6.2% took <80% of prescribed medicines (low Adherence). The reasons for missed doses were significantly associated with the adherence levels (p < 0.05). Gender, age of child and mother, level of education and occupation of the mothers did not significantly affect the level of adherence. (p > 0.05). Conclusions: The adherence rates found in this study are comparable to other studies in developing countries. But these rates are still low for good clinical outcomes. Different levels of adherence were documented with the majority having good or high adherence. Not all of the infants started treatment at birth and Institutional delivery should be encouraged to improve early initiation of prophylaxis. The finding of patients with low

References

[1]  UNAIDS (2011) Report on the Global HIV/AIDS Epidemic. UNAIDS, Geneva.
[2]  AVERT. Prevention of Mother-to-Child Transmission (PMTCT) of HIV.
[3]  Newell, M. (2006) Current Issues in the Prevention of Mother to Child Transmission of HIV-1. Transactions of the Royal Society of Tropical Medicine and Hygiene, 100, 1-5.
https://doi.org/10.1016/j.trstmh.2005.05.012
[4]  Federal Government of Nigeria (2011) National Guidelines on Prevention of Mother to Child Transmission (PMTCT) of HIV in Nigeria. Federal Ministry of Health, Abuja, Nigeria.
[5]  Bedri, A., Gudetta, B., Isehak, A., Kumbi, S., Lulseged, S. and Six Week Extended-Dose Nevirapine (SWEN) Study Team (2006) Extended-Dose Nevirapine to 6 Weeks of Age for Infants to Prevent HIV Transmission via Breastfeeding in Ethiopia, India, and Uganda: An Analysis of Three Randomized Controlled Trials. The Lancet, 372, 300-313.
https://doi.org/10.1016/S0140-6736(08)61114-9
[6]  Coovadia, H.M., Brown, E.R., Fowler, M.G., Chipato, T., Moodley, D. and Manji, K. (2012) Efficacy and Safety of an Extended Nevirapine Regimen in Infant Children of Breastfeeding Mothers with HIV-1 Infection for Prevention of Postnatal HIV-1 Transmission (HPTN 046): A Randomized, Double-Blind, Placebo-Controlled Trial. The Lancet, 379, 221-228.
https://doi.org/10.1016/S0140-6736(11)61653-X
[7]  Chasela, C., Hudgens, M., Jamieson, D., Kayira, D., Hosseinipour, M.C., Kourtis, A.P., et al. (2010) Maternal or Infant Antiretroviral Drugs to Reduce HIV-1 Transmission. The New England Journal of Medicine, 362, 2271-2281. https://doi.org/10.1056/NEJMoa0911486
[8]  Cohen, K., Hopkins, J., Ingraham, R., et al. (1991) Characterisation of the Binding Site for Nevirapine, a Non-Nucleoside Inhibitor of HIV Type 1 Reverse Transcriptase. The Journal of Biological Chemistry, 266, 14670-14685.
[9]  Montaner, J., Reiss, P., Cooper, D., et al. (1998) A Randomized, Double-Blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected Patients: The INCAS Trial. JAMA, 279, 930-937. https://doi.org/10.1001/jama.279.12.930
[10]  D’Aquila, R., Hughes, M., Johnson, V., et al. (1996) Nevirapine, Zidovudine and Didanosine Compared with Zidovudine and Didanosine in Patients with HIV-1 Infection. A Randomized, Double-Blind, Placebo-Controlled Trial. ACTG 241. Annals of Internal Medicine, 124, 1019-1030. https://doi.org/10.7326/0003-4819-124-12-199606150-00001
[11]  Richman, D., Havlir, D., Corbeil, J., et al. (1994) Nevirapine Resistance Mutations of Human Immunodeficiency Virus Type 1 Selected during Therapy. Journal of Virology, 68, 1660-1666.
[12]  De Jong, M., Vella, S., Carr, A., et al. (1997) High-Dose Nevirapine in Previously Untreated HIV Type-1 Infected Persons Does Not Result in Sustained Suppression of Virus Replication. The Journal of Infectious Diseases, 175, 966-970. https://doi.org/10.1086/514002
[13]  Thomas, T.K., Masaba, R. et al. (2011) Triple-Antiretroviral Prophylaxis to Prevent Mother-to-Child Transmission through Breastfeeding—The Kisumu Breastfeeding Study. Kenya: A Clinical Trial. PLoS Medicine, 8, e1001015. https://doi.org/10.1371/journal.pmed.1001015
[14]  World Health Organisation (2010) PMTCT Strategic Vision, 2010-2015. Preventing Mother-to-Child Transmission of HIV to Reach the UNGASS and Millennium Development Goals.
http://www.who.int/hiv/pub/mtct/strategic_vision/en
[15]  McMahon, J.H., Jordan, M.R., Kelley, K., Bertagnolio, S., Hong, S.Y., Wanke, C.A., et al. (2011) Pharmacy Adherence Measures to Assess Adherence to Antiretroviral Therapy: Review of the Literature and Implication for Treatment Monitoring. HIV/AIDS, 52, 493-506.
https://doi.org/10.1093/cid/ciq167
[16]  McNabb, J., Ross, J.W., Abriola, K., Turley, C., Nightingale, C.H. and Nicolau, D.P. (2001) Adherence to Highly Active Antiretroviral Therapy Predicts Virologic Outcome at an Inner-City Human Immunodeficiency Virus Clinic. HIV/AIDS, 33, 700-705. https://doi.org/10.1086/322590
[17]  Mills, E.J., Nachega, J.B., Buchan, I., Orbinski, J., Attaran, A., Singh, S., et al. (2006) Adherence to Antiretroviral Therapy in Sub-Saharan Africa and North America. JAMA, 296, 679-690.
https://doi.org/10.1001/jama.296.6.679
[18]  Orrell, C., Bangsberg, D., Badri, M. and Wood, R. (2003) Adherence Is Not a Barrier to Successful Antiretroviral Therapy in South Africa. AIDS, 17, 1369-1375.
https://doi.org/10.1097/00002030-200306130-00011
[19]  Palumbo, P., Lindsey, J.C., Hughes, M.D., Cotton, M.F., Bobat, R., Meyers, T., Bwakura-Dangarembiz, M., Chi, B.H., Musoke, P., Kamthunzi, P., Schimana, W., Purdue, L., Eshleman, S.H., Abrams, E.J., Millar, L., Petzold, E., Mofenson, L.M., Jean-Philippe, P. and Violari, A. (2010) Antiretroviral Treatment for Children with Peripartum Nevirapine Exposure. The New England Journal of Medicine, 363, 1510-1520. https://doi.org/10.1056/NEJMoa1000931
[20]  NIAID (2004) Paediatric AIDS Clinical Trials Group.
[21]  Zegeye, S. and Sendo, H.G. (2015) Adherence to Antiretroviral Therapy among HIV-Infected Children Attending HiwotFana and Dil-Chora ART Clinic at Referral Hospitals in Eastern Ethiopia. Journal of HIV for Clinical and Scientific Research, 2, 8-14.
https://doi.org/10.17352/2455-3786.000007
[22]  Nicastri, E., Leone, S., Angeletti, C., Palmisano, L., Sarmati, L., Chiesi, A., Geraci, A., Vella, S., Narciso, P., Corpolongo, A. and Andreoni, M. (2007) Sex Issues in HIV-1-Infected Persons during Highly Active Antiretroviral Therapy: A Systematic Review. Journal of Antimicrobial Chemotherapy, 60, 724-732. https://doi.org/10.1093/jac/dkm302
[23]  Prins, M., Meyer, L. and Hessol, N.A. (2005) Sex and the Course of HIV Infection in the Pre- and Highly Active Antiretroviral Therapy Eras. AIDS, 19, 357-370.
https://doi.org/10.1097/01.aids.0000161765.75663.27
[24]  Collazos, J., Asensi, V. and Cartón, J.A. (2007) Sex Differences in the Clinical, Immunological and Virological Parameters of HIV-Infected Patients Treated with HAART. AIDS, 21, 835-843. https://doi.org/10.1097/QAD.0b013e3280b0774a
[25]  Berg, K.M., Demas, P.A., Howard, A., Schoenbaum, E.E., Gourevitch, M.N. and Arnsten, J.H. (2004) Gender Differences in Factors Associated with Adherence to Antiretroviral Therapy. Journal of General Internal Medicine, 19, 1111-1117.
https://doi.org/10.1111/j.1525-1497.2004.30445.x
[26]  Tapp, C., Milloy, M.J., Kerr, T., Zhang, R., Guillemi, S., Hogg, R.S., Montaner, J. and Wood, E. (2011) Female Gender Predicts Lower Access and Adherence to Antiretroviral Therapy in a Setting of Free Healthcare. BMC Infectious Diseases, 11, 86.
https://doi.org/10.1186/1471-2334-11-86
[27]  Chesney, M.A. (2000) Factors Affecting Adherence to Antiretroviral Therapy. Clinical Infectious Diseases, 30, S171-S176. https://doi.org/10.1086/313849
[28]  Liu, H., Golin, C.E., Miller, L.G., Hays, R.D., Beck, C.K., Sanandaji, S., Christian, J., Maldonado, T., Duran, D., Kaplan, A.H. and Wenger, N.S. (2001) A Comparison of Multiple Measures of Adherence to HIV Protease Inhibitors. Annals of Internal Medicine, 136, 175.
https://doi.org/10.7326/0003-4819-134-10-200105150-00011
[29]  Nemes, M.I.B., Carvalho, H.B. and Souza, M.F.M. (2004) Antiretroviral Therapy Adherence in Brazil. AIDS, 18, S15-S20. https://doi.org/10.1097/00002030-200406003-00004
[30]  Weiser, S. and Hardon, L. (2003) Barriers to Antiretroviral Adherence for Patients Living with HIV Infection and AIDS in Botswana. Journal Acquired Immune Deficiency Syndrome, 34, 281-288. https://doi.org/10.1097/00126334-200311010-00004
[31]  Safren, S.A., Kumarasamy, N., James, R., Raminani, S., Solomon, S. and Mayer, K.H. (2005) ART Adherence, Demographic Variables and CD4 Outcome among HIV-Positive Patients on Antiretroviral Therapy in Chennai, India. AIDS Care, 17, 853-862.
https://doi.org/10.1080/09540120500038439
[32]  Desmond, A., Moodley, D. and Coovadia, H. (2015) Evaluation of Adherence Measures of Antiretroviral Prophylaxis in HIV Exposed Infants in the First 6 Weeks of Life. BMC Pediatrics, 15, 23. https://doi.org/10.1186/s12887-015-0340-9
[33]  Müller, A.D., Bode, S., Myer, L., Roux, P. and von Steinbüchel, N. (2008) Electronic Measurement of Adherence to Pediatric Antiretroviral Therapy in South Africa. The Pediatric Infectious Disease Journal, 27, 257-262. https://doi.org/10.1097/INF.0b013e31815b1ad4
[34]  Bagenda, A., Barlow-Mosha, L., Bagenda, D., Sakwa, R., Fowler, M.G. and Musoke, P.M. (2011) Adherence to Tablet and Liquid Formulations of Antiretroviral Medication for Pediatric HIV Treatment at an Urban Clinic in Uganda. Annals of Tropical Paediatrics, 31, 235-245.
https://doi.org/10.1179/1465328111Y.0000000025
[35]  Bartlett, J.A. (2002) Addressing the Challenges of Adherence. JAIDS Journal of Acquired Immune Deficiency Syndromes, 29, 2-10. https://doi.org/10.1097/00126334-200202011-00002
[36]  Shetty, A.K., Coovadia, H.M., Mirochnick, M.M., Maldonado, Y., Mofenson, L.M., Eshelman, S.H., et al. (2003) Safety and Trough Concentrations of Nevirapine Prophylaxis Given Daily, Twice Weekly, or Weekly in Breast-Feeding Infants from Birth to 6 Months. Journal of Acquired Immune Deficiency Syndromes, 34, 482-490.
https://doi.org/10.1097/00126334-200312150-00006
[37]  Müller, A.D., Jaspan, H.B., Myer, L., Hunter, A.L., Harling, G., Bekker, L.G., et al. (2011) Standard Measures Are Inadequate to Monitor Pediatric Adherence in a Resource-Limited Setting. AIDS and Behavior, 15, 422-431. https://doi.org/10.1007/s10461-010-9825-6
[38]  Mirkuzie A.H., Hinderaker, S.G., Sisay, M.M., Moland, K.M. and Mørkve, O. (2011) Current Status of Medication Adherence and Infant Follow Up in the Prevention of Mother to Child HIV Transmission Programme in Addis Ababa: A Cohort Study. Journal of the International AIDS Society, 14, 50.
http://www.jiasociety.org/content/14/1/50
[39]  Mirkuzie, A.H., Hinderaker, S.G., Sisay, M.M., Moland, K.M. and Mørkve, O. (2011) Current Status of Medication Adherence and Infant Follow up in the Prevention of Mother to Child HIV Transmission Programme in Addis Ababa: A Cohort Study. Journal of the International AIDS Society, 14, 50.
https://doi.org/10.1186/1758-2652-14-50
[40]  Stringer, E., Ekouevi, D.K., Coetzee, D., Tih, P.M., Creek, T.L., Stinson, K., Giganti, M.J., Welty, T.K., Chintu, N., Chi, B.H., Wilfert, C.M., Shaffer, N., Dabis, F. and Stringer, J.S. (2010) Coverage of Nevirapine-Based Services to Prevent Mother-to-Child HIV Transmission in 4 African Countries. The Journal of the American Medical Association, 304, 293-302.
[41]  Dabis, F., Bequet, L., Ekouevi, D.K., Viho, I., Rouet, F., Horo, A., Sakarovitch, C., Becquet, R., Fassinou, P., Dequae-Merchadou, L., Welffens-Ekra, C., Rouzioux, C. and Leroy, V. (2005) Field Efficacy of Zidovudine, Lamivudine and Single-Dose Nevirapine to Prevent Peripartum HIV Transmission. AIDS, 19, 309-318.
[42]  Volmink, J., Siegfried, N.L., Van der Merwe, L. and Brocklehurst, P. (2007) Antiretrovirals for Reducing the Risk of Mother-to-Child Transmission of HIV Infection. Cochrane Database of Systematic Reviews, No. 7, CD003510. https://doi.org/10.1002/14651858.CD003510.pub2
[43]  Kuonza, L., Tshuma, C.D., Shambira, G.N. and Tshimanga, M. (2010) Non-Adherence to the Single Dose Nevirapine Regimen for the Prevention of Mother-to-Child Transmission of HIV in Bindura Town, Zimbabwe: A Cross-Sectional Analytic Study. BMC Public Health, 10, 218. https://doi.org/10.1186/1471-2458-10-218
[44]  Ilomuanya, M.O., Okubanjo, O.O., Azubuike, C.P. and Oguntibeju, A. (2017) Evaluation of the Frequency of Use of Herbal Drugs with Concomitant Administration of Highly Active Antiretroviral Therapy and Its Effect on Medication Adherence in Two Health Care Facilities in South Western Nigeria. Journal of AIDS and HIV Research, 9, 8-16.
[45]  Barner, A. and Myers, M. (1998) Nevirapine and Rashes. The Lancet, 351, 1133.
https://doi.org/10.1016/S0140-6736(05)79417-4
[46]  Havlir, D., Cheesman, S., McLaughin, M., et al. (1995) High-Dose of Nevirapine: Safety, Pharmacokinetics, and Antiviral Effect in Patients with HIV Infection. The Journal of Infectious Diseases, 171, 537-545. https://doi.org/10.1093/infdis/171.3.537
[47]  Warren, K., Boxwell, D., Kim, N. and Drolet, B. (1998) Nevirapine Associated Stevens Johnson Syndrome. The Lancet, 351, 567. https://doi.org/10.1016/S0140-6736(98)24008-6
[48]  Antón, P., Soriano, V., Jiménez-Nácher, I., et al. (1999) Incidence of Rash and Discontinuation of Nevirapine Using Two Different Escalating Initial Doses. AIDS, 13, 524-525.
https://doi.org/10.1097/00002030-199903110-00013
[49]  Barreiro, P., et al. (2000) Prevention of Nevirapine-Associated Exanthema Using Slow Dose Escalation and/or Corticosteroids. AIDS, 14, 2153-2157.
https://doi.org/10.1097/00002030-200009290-00012

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133